Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, January 22, 2024
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
[ Mon, Jan 22nd 2024
] - WOPRAI
Joseph Stringer Maintained (CARA) at Strong Buy with Decreased Target to $5 on, Jan 22nd, 2024
Joseph Stringer of Needham, Maintained "Cara Therapeutics, Inc." (CARA) at Strong Buy with Decreased Target from $6 to $5 on, Jan 22nd, 2024.
Joseph has made no other calls on CARA in the last 4 months.
There are 2 other peers that have a rating on CARA. Out of the 2 peers that are also analyzing CARA, 1 agrees with Joseph's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- David Amsellem of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $1 on, Tuesday, November 14th, 2023
This is the rating of the analyst that currently disagrees with Joseph
- Oren Livnat of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $2.5 on, Tuesday, December 19th, 2023
